Tilray Brands (TLRY) Share-based Compensation (2017 - 2026)
Tilray Brands' (TLRY) quarterly Share-based Compensation came in at $14.9 million in Q2 2026, up 143.93% YoY from $6.1 million in Q2 2025, and up 8.42% on a QoQ basis from $13.7 million in Q1 2026.
Tilray Brands (TLRY) Share-based Compensation (2017 - 2026) Analysis & Trends
Tilray Brands (TLRY) has 10 years of Share-based Compensation data on file, last reported at $14.9 million in Q2 2026.
- Quarterly Share-based Compensation rose 143.93% year-over-year to $14.9 million in Q2 2026, while the trailing twelve-month figure through May 2026 was $45.9 million (up 89.14% YoY) and the FY2026 annual result came in at $45.9 million, up 89.14% from the prior year.
- Share-based Compensation climbed to $14.9 million in Q2 2026, from $13.7 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $14.9 million in Q2 2026 to a low of $4.0 million in Q1 2025.
- A 5-year average of $8.9 million and a median of $8.6 million in 2022 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2025 — Share-based Compensation slumped 49.93% — and 2026, when it surged 240.15%.
- Tracing TLRY's Share-based Compensation over 5 years: stood at $10.9 million in 2022, then fell by 25.06% to $8.2 million in 2023, then fell by 11.75% to $7.2 million in 2024, then jumped by 69.73% to $12.3 million in 2025, then rose by 21.14% to $14.9 million in 2026.
- The last three Share-based Compensation figures came in at $14.9 million (Q2 2026), $13.7 million (Q1 2026), and $12.3 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 40.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 26.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 114.12 Mn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 19.00 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 30.40 Mn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 65.00 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 7.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Tilray Brands | 523.93 Mn | 289.30 Mn | 90.52 Mn | 14.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2026 | 14.88 Mn |
| May 31, 2026 | 14.88 Mn |
| Feb 28, 2026 | 13.73 Mn |
| Feb 28, 2026 | 13.73 Mn |
| Nov 30, 2025 | 12.28 Mn |
| Nov 30, 2025 | 12.28 Mn |
| Aug 31, 2025 | 5.05 Mn |
| Aug 31, 2025 | 5.05 Mn |
| May 31, 2025 | 6.10 Mn |
| May 31, 2025 | 6.10 Mn |
| Feb 28, 2025 | 4.04 Mn |
| Feb 28, 2025 | 4.04 Mn |
| Nov 30, 2024 | 7.24 Mn |
| Nov 30, 2024 | 7.24 Mn |
| Aug 31, 2024 | 6.92 Mn |
| Aug 31, 2024 | 6.92 Mn |
| May 31, 2024 | 7.25 Mn |
| May 31, 2024 | 7.25 Mn |
| Feb 29, 2024 | 8.06 Mn |
| Feb 29, 2024 | 8.06 Mn |